{
  "abstract": "Immune checkpoint inhibitors (ICIs) have improved survival of patients with cancer, yet they pose risks of immune-related adverse events (irAEs). ICI-induced insulin-dependent diabetes mellitus (ICI-DM) is a life-threatening and life-altering irAE. Previously, we reported a high incidence of a germline missense variant in NLRC5, a key class I transcription activator, among patients with ICI-DM compared with similarly treated patients who did not develop ICI-DM. Our purpose was to validate this finding in additional ICI-treated patients and study effects of the NLRC5 variant on expression of class I major histocompatibility complex (MHC) antigen presentation genes.We assessed the prevalence of the C>T missense variant at chr16:57 025 515 (NLRC5Pro191Leu) in germline DNA from an additional 33 patients with ICI-DM and in patients with ICI-induced colitis (n=15), ICI-induced hypothyroidism (n=19) and ICI-induced hypophysitis (n=17). The 1,000 Genomes Project was used for comparison. We assessed peripheral blood mononuclear cells from 16 individuals with or without the NLRC5 variant, studying expression of NLRC5 and select downstream target genes, before and after stimulation with interferon-γ.We validated the higher prevalence of NLRC5Pro191Leu in a non-overlapping cohort of patients with ICI-DM compared with the general population (51.5% vs 12.8%, p<0.0001). The prevalence of NLRC5Pro191Leu in ICI-induced colitis or thyroiditis patients did not significantly differ from the general population, while the prevalence in ICI-induced hypophysitis was somewhat higher (21.6%, p=0.048). We found greater increases in messenger RNA expression of NLRC5 (p=0.007), TAP1 (p=0.0002), B2M (p=0.0005), HLA-G (p=0.04), PSMB8 (p=0.03) and PSMB9 (p=0.01) in NLRC5Pro191Leu cells stimulated with interferon-γ compared with NLRC5WT cells. A similar trend was observed for HLA-A (p=0.09).We confirm the significantly higher prevalence of the NLRC5Pro191Leu variant in patients with ICI-DM relative to the general population. This abundance appears to be unique to patients who develop ICI-DM or hypophysitis on ICIs, underscoring its potential involvement in the pathogenesis of these endocrinopathies. The effects of this NLRC5 variant on class I MHC regulators suggest a mechanistic connection between the variant and development of ICI-DM. Further work is warranted to determine whether class I MHC molecules can be modulated in patients with the NLRC5Pro191Leu variant requiring ICIs.",
  "authors": [
    {
      "affiliations": [
        "Medical Oncology, Yale University, New Haven, Connecticut, USA"
      ],
      "name": "Lilach Aizenbud"
    },
    {
      "affiliations": [
        "Medical Oncology, Yale University, New Haven, Connecticut, USA",
        "Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, USA"
      ],
      "name": "Noam Savion Gaiger"
    },
    {
      "affiliations": [
        "Endocrinology and Metabolism, Yale University, New Haven, Connecticut, USA",
        "Internal medicine, VA Connecticut Healthcare System, West Haven, Connecticut, USA"
      ],
      "name": "Ana Luisa Perdigoto"
    },
    {
      "affiliations": [
        "Medical Oncology, Yale University, New Haven, Connecticut, USA"
      ],
      "name": "Jacqueline E Mann"
    },
    {
      "affiliations": [
        "Endocrinology and Metabolism, Yale University, New Haven, Connecticut, USA"
      ],
      "name": "Madeline Candelas Torres"
    },
    {
      "affiliations": [
        "Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA"
      ],
      "name": "Genevieve M Boland"
    },
    {
      "affiliations": [
        "Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"
      ],
      "name": "Aleigha R Lawless"
    },
    {
      "affiliations": [
        "Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA"
      ],
      "name": "Shahar Silverman"
    },
    {
      "affiliations": [
        "Medical Oncology, Yale University, New Haven, Connecticut, USA",
        "Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, USA"
      ],
      "name": "David Aaron Schoenfeld"
    },
    {
      "affiliations": [
        "Yale University, New Haven, Connecticut, USA"
      ],
      "name": "Jodhel I Destina"
    },
    {
      "affiliations": [
        "Medical Oncology, Yale University, New Haven, Connecticut, USA"
      ],
      "name": "Nitzan Hasson"
    },
    {
      "affiliations": [
        "Medical Oncology, Yale University, New Haven, Connecticut, USA",
        "Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, USA"
      ],
      "name": "Thuy Tran"
    },
    {
      "affiliations": [
        "Medical Oncology, Yale University, New Haven, Connecticut, USA",
        "Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, USA"
      ],
      "name": "Michael Hurwitz"
    },
    {
      "affiliations": [
        "Medical Oncology, Yale University, New Haven, Connecticut, USA"
      ],
      "name": "Matthew R Austin"
    },
    {
      "affiliations": [
        "Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"
      ],
      "name": "Ryan J Sullivan"
    },
    {
      "affiliations": [
        "Endocrinology and Metabolism, Yale University, New Haven, Connecticut, USA",
        "Immunology, Yale University, New Haven, Connecticut, USA"
      ],
      "name": "Kevan C Herold"
    },
    {
      "affiliations": [
        "Medical Oncology, Yale University, New Haven, Connecticut, USA",
        "Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, USA"
      ],
      "name": "Harriet M Kluger"
    }
  ],
  "title": "Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes",
  "uid": "d02b2b2c-155f-5600-bae8-6e3a5d2f1fd5"
}